US-based biotechnology company MOMA Therapeutics has dosed the first patient in its Phase I clinical trial of MOMA-313, a polymerase theta helicase inhibitor.
The multi-centre, open-label study aims to evaluate MOMA-313’s safety and tolerability in patients with solid tumours.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
MOMA-313 is a highly potent and selective oral polymerase theta helicase inhibitor designed to be used in combination with a PARP inhibitor.
The drug targets patients with specific DNA repair gene alterations, including certain subgroups with prostate, pancreatic and breast cancers.
The trial will assess MOMA-313’s efficacy both as a single agent and in combination with the PARP inhibitor olaparib.
MOMA CEO Asit Parikh said: “We are excited to be progressing two molecules with best-in-class potential toward the benefit of cancer patients in need in such close proximity.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“This progress serves as a testament to the excellence and unwavering commitment of the entire MOMA team.”
In addition to this study, MOMA Therapeutics has identified a development candidate for another lead programme, the Werner helicase inhibitor MOMA-341.
MOMA-341 is being developed as a treatment for cancers with microsatellite instability such as colorectal, gastric and endometrial cancers.
It will be tested both as a monotherapy and in combination with other treatments, including chemotherapy and immunotherapy.
MOMA Therapeutics expects to submit an investigational new drug (IND) application for MOMA-341 to the US Food and Drug Administration (FDA) early next year.
Both MOMA-313 and MOMA-341 were discovered and developed using the KNOMATIC platform, which uses structural insights, advanced hit-finding technologies and computational lead optimisation to expedite the discovery of therapeutics targeting dynamic protein families.
MOMA chief scientific officer Peter Hammerman said: “Advancing two highly potent and selective drug candidates derived from our proprietary KNOMATIC platform toward the clinic is a unique privilege.
“The goal with each candidate is to translate groundbreaking science into life-altering medicine.”
